Pfizer Inc. today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company’s robust oncology pipeline. “We are excited to contribute our significant expertise and ...

Pfizer elevated Dr. Chris Boshoff, MD, PhD to serve as chief scientific officer as well as research and development president on Wednesday morning. Boshoff, who has been with Pfizer for more than 11 ...

(Reuters) -Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development, as the drugmaker faces pressure from investors to produce ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases Published Sep 3, 2024 5:00pm EDT ...

Pfizer’s Oncology R&D organization will maintain its fully integrated structure with Roger Dansey, M.D. serving as Interim Chief Oncology Officer, reporting to Dr. Boshoffeffective January 1, 2025.